# Avacta Group Plc A second wake-up call for the market

- Link: https://www.directorstalkinterviews.com/avacta-group-plc-a-second-wake-up-call-for-the-market/412766538
- Published: 2019-02-06T12:22:07+00:00
- Author: Charlotte Edwards

**[⌊Hardman & Co Report Report Downloads⌉⌊Hardman & Co Report Report Downloads⌉[[Avacta](https://www.directorstalkinterviews.com/company/avacta-group-plc/avct.l) Group Plc**([
LON:AVCT](https://www.directorstalkinterviews.com/ftse-company/avacta-group-plc/avct.l)) is a pre-
clinical stage biotechnology company and the proprietary owner of Affimer technology.
Affimers represent a radical alternative to the established antibody technology.
The significant technical and commercial benefits of Affimers are being increasingly
recognised, evidenced by corporate and academic interests, ongoing evaluations and
deal flow. AVCT has just announced that, following a review period, Moderna has 
exercised its option to enter into an exclusive licensing agreement to further develop
certain Affimer therapeutics for undisclosed targets. This is the second licensing
deal with a major pharma player in the past few months.

**Strategy**: AVCT is aiming to commercialise its Affimer technology through licensing
for research and diagnostics, and by identifying and developing its own proprietary
therapeutic pipeline for partnering. AVCT has sufficient cash resources to identify
an Affimer lead and be ready for first-in-man trials in 2020.

**Licensing deal**: Following the deal with LG Chem last December for a total value
of up to $310m, Moderna has now exercised its option to develop certain Affimers
against an undisclosed target. The financial terms have not been disclosed, but 
we expect AVCT to receive near-term development milestones.

**Moderna**: Following its recent IPO in December 2018, which valued the company
at $7.5bn, Moderna is a strong partner in the emerging field of therapeutic mRNA.
With 11 compounds in clinical development, it represents a valuable partner that
further supports and validates the Affimer platform.

**Risks**: Affimers represent a new disruptive technology, and the potential customer
base has taken some time to recognise their advantages. While all new drug development
carries a high risk, AVCT has hit a number of important milestones over the last
two years, greatly reducing the risk profile.

**Investment summary**: Avacta has made considerable progress towards its goal of
having a number of commercial partnerships for its Affimer technology, as well as
developing its own proprietary Affimer-based drugs and growing a separate, profitable
reagents business. The rising number of collaboration deals being discussed and 
signed is clear indication of the long-term value of its Affimer technology, which
the market is currently only just beginning to recognise.

Share on:
